Association of Plasma Biomarkers With Longitudinal Atrophy and Microvascular Burden on MRI Across Neurodegenerative and Cerebrovascular Diseases
Erlan Sanchez, Gillian Coughlan, Tim Wilkinson, Joel Ramirez, Saira Saeed Mirza, Andrée‐Ann Baril, Allison A. Dilliott, Andrew Frank, Anthony E. Lang, Ayman Hassan, Bruce G. Pollock, Christopher J.M. Scott, Connie Marras, Corinne E. Fischer, Dallas Seitz, Daniela Andriuta, Dar Dowlatshahi, David A. Grimes, David F. Tang‐Wai, Demetrios J. Sahlas, Ekaterina Rogaeva, Elizabeth Finger, John F. Robinson, Kübra Tan, Malcolm A. Binns, Maria Carmela Tartaglia, Michael Borrie, Michael J. Strong, Miracle Ozzoude, Nuwan D. Nanayakkara, Rafaella A. Gonçalves, Robert Bartha, Robert A. Hegele, Sali M.K. Farhan, Sandra E. Black, Sanjeev Kumar, Sean Symons, Seyyed Mohammad Hassan Haddad, Stephen Pasternak, Stephen R. Arnott, Tarek K. Rajji, Thomas Steeves, Walter Swardfager, Nicholas J. Ashton, Hlin Kvartsberg, Henrik Zetterberg, Douglas P. Munoz, Mario Masellis, for the ONDRI Investigators
Abstract
BACKGROUND AND OBJECTIVES: Plasma biomarkers of Alzheimer disease (AD), neuroinflammation, and neurodegeneration are increasingly being used in clinical trials for diagnosis and monitoring of dementia. However, their association with longitudinal structural brain MRI changes, an important outcome measure across neurodegenerative and cerebrovascular diseases, is less known. We investigated how baseline plasma biomarkers reflect MRI markers of progression over time in patients with neurodegenerative and cerebrovascular diseases. METHODS: ) diplotypes, waist-hip circumference ratio, and disease duration. RESULTS: = 0.049 to <0.001) in the pooled disease-agnostic group. Within disease-specific cohorts, GFAP and NfL were associated with cerebral atrophy and/or small vessel disease copathology in AD/MCI, PD, FTD, or CVD. P-tau181 and p-tau217 were associated with cerebral atrophy and/or small vessel disease copathology in AD/MCI, CVD, PD-MCI, or PD-dementia. DISCUSSION: Selected plasma biomarkers seem useful as prognosis and monitoring tools of longitudinal imaging changes within real-world populations of neurodegenerative and/or cerebrovascular diseases, and provide insight into overlap across diseases in shared pathologic burden.